Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
85.6M
-
Number of holders
-
122
-
Total 13F shares, excl. options
-
64.3M
-
Shares change
-
-818K
-
Total reported value, excl. options
-
$421M
-
Value change
-
-$5.93M
-
Put/Call ratio
-
0.27
-
Number of buys
-
63
-
Number of sells
-
-42
-
Price
-
$6.55
Significant Holders of Larimar Therapeutics, Inc. - Common Stock (LRMR) as of Q3 2024
135 filings reported holding LRMR - Larimar Therapeutics, Inc. - Common Stock as of Q3 2024.
Larimar Therapeutics, Inc. - Common Stock (LRMR) has 122 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 64.3M shares
of 85.6M outstanding shares and own 75.13% of the company stock.
Largest 10 shareholders include DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (21.2M shares), RA CAPITAL MANAGEMENT, L.P. (6.05M shares), JANUS HENDERSON GROUP PLC (5.57M shares), GOLDMAN SACHS GROUP INC (4.25M shares), Blue Owl Capital Holdings LP (4.17M shares), BlackRock, Inc. (2.97M shares), VANGUARD GROUP INC (2.3M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.7M shares), Driehaus Capital Management LLC (1.28M shares), and Woodline Partners LP (1.24M shares).
This table shows the top 122 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.